M atrix metalloproteinase-2 (MMP-2) is a zinc-dependent protease that is best known for its ability to degrade the extracellular matrix in both physiological and pathological conditions. MMP-2 is synthesized as a zymogen by a variety of cells, including cardiac myocytes, and is activated either by proteases 1 (such as by action of or by posttranslational modifications to the full-length enzyme caused by enhanced oxidative stress. For example, peroxynitrite, which is generated in early reperfusion after ischemia, 2 directly activates several MMPs, 3 including MMP-2, 4 via a nonproteolytic mechanism involving the S-glutathiolation of a critical propeptide cysteine in its autoinhibitory domain.
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MMPs are best recognized for their role in tissue remodeling by proteolyzing various components of the extracellular matrix in both health and disease, ie, in angiogenesis, embryogenesis, wound healing, 5 atherosclerosis, 6 aortic aneurysm, 7 and myocardial infarction. 8 More recent studies, however, show that MMP-2 is involved in several acute biological processes independently of its actions on extracellular matrix proteins. This includes platelet activation, 9 regulation of vascular tone, 10 and myocardial stunning injury immediately after reperfusion of the ischemic heart. 11 Indeed, several reports indicate that MMP-2 does not exclusively degrade extracellular matrix components. 12, 13 In normal cardiac myocytes, MMP-2 is found in discrete subcellular compartments, including the thin and thick myofilaments of the cardiac sarcomere, 14, 15 cytoskeleton, 16, 17 nuclei, 18 mitochondria, 14 and caveolae 19 (see Schulz 20 ) . MMP-2 is activated in rat hearts subjected to myocardial oxidative stress injury and is responsible for the degradation of specific sarcomeric and cytoskeletal proteins, including troponin I, 14, 21 myosin light chain-1, 15 and ␣-actinin. 17 Inhibition of MMP activity reduced both the loss of contractile function and the degradation of these substrates, to which MMP-2 was colocalized. Furthermore, transgenic mice with myocardium-specific expression of a mutant, constitutively active MMP-2, in the absence of additional injury, show significantly impaired cardiac contractile function, disrupted sarcomeres, profound myofilament lysis, breakdown of Z-band registration, and reduced troponin I level. 22 Titin, the largest known mammalian protein (3000 to 4000 kDa), forms an intrasarcomeric elastic filament that is thought to serve as a framework for the ordered assembly of other myofilament proteins. 23 In the sarcomere, the titin molecule spans the distance from the Z-disk to the M-line region (half the length of the sarcomere). Moreover, the I-band region of titin comprises distinct elastic segments that allow titin to behave as a molecular spring, contributing to the passive tension of myofibrils and maintaining the structural and functional stability of the sarcomere. Titin is an important determinant of both systolic and diastolic function and the Frank-Starling mechanism of the heart. 24 Although loss and/or disorganization of titin in ischemic and failing human hearts has been reported, 25, 26 the mechanism of titin degradation has not been extensively studied in hearts subjected to ischemia/reperfusion (I/R) injury. Because MMP-2 is localized to sarcomeric and cytoskeletal proteins and is activated in myocardial I/R injury, we address here whether MMP-2 targets titin to contribute to the pathogenesis of myocardial I/R injury.
Methods

Titin Isolation and Purification
Titin was prepared as described previously. 27, 28 See the online-only Data Supplement.
Skinned Cardiomyocyte Isolation
Skinned cardiomyocytes were isolated as described in the onlineonly Data Supplement.
Cleavage of Native Titin in Skinned Cardiomyocytes
Skinned cardiomyocytes were incubated with human recombinant MMP-2 catalytic domain (4 to 120 nmol/L; Enzo Life Sciences, Plymouth Meeting, Pa) with or without MMP inhibitors (10 mol/L o-phenanthroline or ONO-4817) at 37°C for 60 minutes. This concentration of o-phenanthroline inhibits MMP-2 activity under similar in vitro conditions. 29 The samples were denatured with 2ϫ urea sample buffer (8 mol/L urea, 2 mol/L thiourea, 3% SDS, 75 mmol/L DTT, 0.03% bromophenol blue, and 0.05 mol/L TrisHCl, pH 6.8) at 60°C for 10 minutes, and the proteins were electrophoresed by 1% SDS-agarose and stained with Coomassie brilliant blue.
Isolated Working Rat Heart: Ex Vivo Model of I/R
Male Sprague-Dawley rats (300 to 350 g) were anesthetized with sodium pentobarbital (60 mg/kg IP). Hearts were isolated and paced at 300 bpm during perfusion at 37°C as working hearts 30 with 100 mL recirculating Krebs-Henseleit solution containing 118 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L KH 2 PO 4 , 1.2 mmol/L MgSO 4 , 25 mmol/L NaHCO 3 , 11 mmol/L glucose, 100 U/mL insulin, 2.5 mmol/L Ca 2ϩ , 0.5 mmol/L EDTA, and 0.1% BSA continuously gassed with 95% O 2 /5% CO 2 (pH 7.4). The perfusate enters the left atrium at a hydrostatic preload pressure of 9.5 mm Hg, and the left ventricle ejects it against a hydrostatic afterload of 70 mm Hg. Cardiac work (cardiac output times peak systolic pressure) was used as an index of mechanical function. After 25 minutes of equilibration, hearts were either aerobically perfused for 85 minutes (control; nϭ6) or subjected to 25 minutes of global, no-flow ischemia followed by 60 minutes aerobic reperfusion without (I/R; nϭ7) or with 50 mol/L ONO-4817 (I/RϩONO-4817; nϭ8). ONO-4817, a Figure 1 . Colocalization of MMP-2 and titin at the Z-disk region of the left ventricular cardiac sarcomere in rat hearts aerobically perfused for 10 minutes (longitudinal sections). MMP-2 shows better colocalization with T12 than the M8 epitope of titin in the sarcomere of the left ventricular myocardium. MMP-2-immunoreactivity reveals at Z lines with high density and M lines with low density. T12 epitope reveals at only Z lines, and M8 epitope reveals at only M-lines. A through C, High density of MMP-2 (green) colocalizes (yellow) with T12 epitope (red) at the Z lines. D through F, Low density of MMP-2 (red) colocalizes (yellow) with M8 epitope (green) at M lines. Scale barϭ5 m for all images except the enlarged portion of C illustrating the Z and M lines. selective MMP inhibitor (K i in the nanomolar range for MMP-2 and almost no inhibitory activity up to 100 mol/L against several other proteases of different classes 31 ), was added to the perfusion buffer 10 minutes before the induction of ischemia. All hearts were perfused for a total of 110 minutes. At the end of perfusion, the ventricles were rapidly frozen in liquid nitrogen and processed for titin analysis in ventricular extracts as described below.
Additional series of hearts (control, nϭ5; I/R, nϭ5; and I/RϩONO-4817, nϭ4) were perfused and processed for immunohistochemistry and confocal microscopy analysis for assessment of titin immunostaining. Another 6 hearts were briefly perfused for 10 minutes at 37°C with Krebs-Henseleit buffer at a constant hydrostatic pressure of 70 mm Hg to clear them of blood, followed by processing for immunohistochemistry as described below to investigate the colocalization of titin and MMP-2 in the left ventricle.
This investigation conforms to the Guide to the Care and Use of Experimental Animals published by the Canadian Council on Animal Care.
In Vivo Model of I/R
I/R was induced in vivo by modifying a previously described protocol. 32 Briefly, MMP-2 knockout and age-matched wild-type male C57BL/6 mice were anesthetized with isoflurane, intubated, and kept on a heating pad to maintain body temperature at 37°C. The heart was exposed, and the left anterior descending coronary artery was temporarily ligated with a 7-0 silk suture, with a piece of 4-0 silk placed between the left anterior descending coronary artery and the 7-0 silk. After 30 minutes of left anterior descending coronary artery occlusion, reperfusion was initiated by releasing the ligature and removing the 4-0 silk. The loosened suture was left in place to help identify the ischemic area of the left ventricle. After 30 minutes of reperfusion, the hearts were excised, and the ischemic and nonischemic regions of the left ventricle were dissected out under a magnifying glass and flash frozen in liquid nitrogen for titin analysis.
Analysis of Titin by Gel Electrophoresis
Titin was analyzed in ventricular extracts using 1% vertical SDSagarose gel electrophoresis as previously described. 33 See the onlineonly Data Supplement for details.
Immunohistochemistry and Confocal Microscopy
Colocalization of Titin and MMP-2
Rat hearts perfused aerobically for 10 minutes to flush them of blood or left ventricular tissue from the explanted heart of a heart transplant patient was fixed with 4% paraformaldehyde in 0.1 mol/L sodium phosphate buffer (pH 7.4) and cryoprotected with 30% sucrose in 0.1 mol/L sodium phosphate buffer. Details of the double immunolabeling are provided in the online-only Data Supplement.
Titin 9D10 Immunostaining
At the end of the 110 minutes of working heart perfusion protocol, some control, I/R, or I/RϩONO-4817 hearts were fixed and cryoprotected (as described above) for 9D10 immunostaining as detailed in the online-only Data Supplement.
Overlay Assay to Determine MMP-2 Binding to Titin
Skinned muscle fibers were incubated with trypsin to increase titin degradation (intact T1 to T2 fragment). The proteins in the samples were separated by gel electrophoresis and transferred to a polyvinylidene difluoride membrane. These membranes were used in an overlay assay in which the binding of human recombinant MMP-2 to titin T1 and T2 on the membrane was assessed. For details, see the online-only Data Supplement.
Statistical Analysis
Results are expressed as meanϮSEM for n hearts. As appropriate, 1-way ANOVA or repeated-measures 2-way ANOVA followed by the Tukey posthoc test was used. Differences were considered significant at PϽ0.05.
Results
Colocalization of MMP-2 and Titin Near the Z-Disk Region of the Cardiac Sarcomere
We first investigated whether MMP-2 is localized to titin in the cardiac sarcomere. In this regard, we used 2 different anti-titin antibodies that target specific epitopes ( Figure IA in the online-only Data Supplement). The T12 antibody labels titin near the Z-disk region of titin, and the M8 antibody recognizes an epitope at the M-line region of titin. Images obtained by immunohistochemistry followed by confocal microscopy showed that T12 immunoreactivity distributes near Z lines and M8 immunoreactivity is alternatively distributed at M lines without overlapping ( Figure IB in the online-only Data Supplement). Images obtained with anti-MMP-2 and anti-titin T12 in left ventricle sections from rat hearts aerobically perfused for 10 minutes showed clear colocalization of MMP-2 to the Z-disk region of titin ( Figure  1 ). When using anti-titin M8, we observed a weaker localization of MMP-2 to this region of titin ( Figure 1 ). These data suggest that MMP-2 localizes mainly near the Z-disk region of the sarcomere, with a secondary and weaker localization near the M-line portion in the titin molecule.
MMP-2 Binds and Cleaves Titin in a Concentration-Dependent Manner
In silico mapping of MMP-2 cleavage sites in both human and mouse N2B titin revealed multiple putative sites in both 
Effect of ONO-4817 on Functional Recovery of I/R Hearts
Isolated working rat hearts were perfused for 110 minutes under 1 of 3 conditions: aerobic perfusion (control); 25 minutes of global, no-flow ischemia and 60 minutes of aerobic reperfusion (I/R); or I/R in the presence of a selective MMP inhibitor, ONO-4817 (I/RϩONO-4817; Figure 3A ). Control hearts showed no significant loss of mechanical function over 110 minutes of aerobic perfusion ( Figure 3 ). I/R hearts showed markedly reduced recovery of mechanical function during reperfusion compared with control hearts ( Figure 3B ). The recovery of cardiac work during reperfusion was significantly improved after MMP inhibition with ONO-4817, compared with the I/R group ( Figure 3B ).
Myocardial I/R Causes Titin Cleavage, an Effect Diminished by an MMP Inhibitor
To investigate whether MMP-2 can cleave titin in the intact heart under pathophysiological conditions, titin content was assessed with 1% vertical SDS-agarose gels in ventricular extracts prepared from the control, I/R, or I/RϩONO-4817 hearts. Ventricular extracts from control hearts revealed a titin band at Ϸ3000 kDa ( Figure 4A ). I/R caused a significant increase in T2 band density, an effect abolished in the I/RϩONO-4817 hearts ( Figure 4A ). Quantification of the ratio of total titin to myosin heavy chain (MHC) showed that I/R did not significantly change this ratio compared with control hearts ( Figure 4B ), whereas the ratio of T2 to MHC was significantly increased in I/R hearts. ONO-4817 abolished the I/R-induced increase in the T2/MHC ratio ( Figure  4C ). These observations were further confirmed by immunohistochemistry experiments using the anti-titin 9D10 antibody, raised against the proline-glutamate-valine-lysine (PEVK) domain in the spring region of titin. Titin immuno- staining was significantly reduced by I/R, whereas ONO-4817 treatment preserved titin immunostaining to a level comparable to control ( Figure 4D ).
Titin Degradation Is Reduced in Hearts From MMP-2 Knockout Mice Subjected to I/R Injury In Vivo
We next determined whether genetic ablation of MMP-2 could influence titin degradation in cardiac muscle. Mouse hearts subjected in vivo to left anterior descending coronary artery ligation for 30 minutes followed by 30 minutes of reperfusion exhibited titin degradation, which was significantly less in MMP-2 knockout hearts than in wild-type control hearts ( Figure 5 ).
MMP-2 Localizes Near the Z-Disk Region of Titin in the Human Heart
Immunostaining of sections prepared from the left ventricle of an explanted heart from a patient undergoing heart transplantation showed colocalization of MMP-2 and titin mainly near the Z disk, with a weaker colocalization at the M line. Compared with the rat heart, MMP-2 immunostaining in the human heart was more diffuse yet still showed a sarcomeric staining pattern ( Figure 6 ).
Discussion
In this study, we demonstrated that titin, the giant sarcomeric protein, is a target of the proteolytic activity of MMP-2 in the setting of acute myocardial I/R injury. Immunohistochemical analysis shows that MMP-2 clearly colocalizes with titin near the Z-disk region of the sarcomere in both rat and human hearts. We established that under in vitro conditions MMP-2 is able to bind to and cleave titin in a concentration-dependent manner. The proteolytic action of MMP-2 is blocked by the selective MMP inhibitors GM-6001 and ONO-4817, verifying that the cleavage is indeed due to MMP activity. ONO-4817 not only improves the functional recovery after I/R in isolated rat hearts but also prevents the significant increase in the titin degradation product T2 caused by I/R injury, indicating that titin degradation is reduced when MMP activity is . Titin degradation in I/R rat hearts. A, Representative SDS-agarose gel for analysis of titin in ventricular extracts. Titin (T1) and titin degradation product (T2) in ventricular homogenates from control, I/R, and I/RϩONO-4817 hearts analyzed with a 1% vertical SDSagarose gel. Bovine left ventricle (BLV) was used as a standard and shows N2BA and N2B isoforms of titin; note that the majority of rat heart titin is the N2B isoform. Each lane is an extract from individually perfused hearts. B, Ratio of total titin (T1ϩT2) to MHC content (nϭ6 in each group). C, Ratio of T2 titin to MHC content (nϭ6 in each group). *PϽ0.05 vs control (1-way ANOVA, Tukey posthoc test). D, Representative left ventricular cryosections immunostained against titin epitope 9D10. Titin immunostaining with the 9D10 antibody (raised against the PEVK domain) was decreased in I/R hearts vs control, whereas staining intensity was comparable between I/RϩONO-4817 and control hearts. Scale barϭ10 m for all images. Images are representative of at least 4 individual hearts investigated under each condition.
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inhibited. Furthermore, hearts from MMP-2 knockout mice subjected to in vivo I/R injury show less titin degradation compared with wild-type controls. Titin proteolysis has been observed in various human heart diseases associated with increased myocardial oxidative stress, including dilated cardiomyopathy, the terminally failing heart, and Chagas cardiomyopathy 25, 26, 34 ; however, the proteases responsible for this were not identified. MMPs are best known as proteases responsible for the degradation and remodeling of extracellular matrix proteins in both physiological and pathological conditions, including various cardiac pathologies. However, the discovery of the intracellular localization 14, 16, 18, 22 and functions of MMP-2 to proteolyze troponin I, 14, 22 myosin light chain-1, 15 and ␣-actinin 17 during myocardial oxidative stress injury challenged the canonical notion of extracellular-only actions of this enzyme. In previous studies, we showed that peroxynitrite biosynthesis in I/R rat hearts peaks within the first minute of reperfusion 2 and that the peak in MMP-2 activity follows at 2 to 5 minutes of reperfusion. 11 Infusion of peroxynitrite into isolated perfused rat hearts 35 or isolated cardiomyocytes 36 caused a time-and concentrationdependent contractile dysfunction that was abrogated with MMP inhibitors. In vitro, peroxynitrite was shown to directly activate MMP-2 via a nonproteolytic mechanism involving S-glutathiolation of the propeptide cysteine sulfydryl group. 4 Indeed, this intracellular activity of MMP-2 on I/R injury caused proteolytic degradation of specific sarcomeric (troponin I 14 and myosin light chain-1 15 ) and cytoskeletal (␣-actinin 17 ) proteins that are susceptible to its proteolytic activity.
MMP-2 is localized within the cardiac sarcomere, including near the Z disks. 14 -16 These previous observations are supplemented by the present data showing clear colocalization of MMP-2 near the Z-disk region of titin using the T12 clone in rat ( Figure 1 ) and human ( Figure 6 ) hearts. Several studies show that titin interacts with ␣-actinin at the Z disk of the sarcomere and that this interaction plays a crucial role in Z-disk assembly and sarcomeric integrity. [37] [38] [39] Interestingly, MMP-2 was found not only to colocalize with ␣-actinin in the Z disk of cardiac sarcomeres 16, 17 but also to degrade it after peroxynitrite infusion into isolated rat hearts. 17 The M8 titin antibody (raised against the M-line region of titin) shows a weaker localization of MMP-2 to this region of titin. Although our data do not rule out the possible localization of MMP-2 also to other region(s) of titin, they do suggest that a main MMP-2 anchoring site is at/near the Z disk of the sarcomere.
Titin is the third myofilament (in addition to thick and thin myofilaments) of the sarcomere that plays an important role in sarcomere integrity and cardiac muscle contraction. 23 Any alterations in its structure could severely affect the contractile performance of the heart. The increase in T2 titin and the decrease in titin immunostaining after I/R injury observed here ( Figure 4) were associated with poor cardiac mechanical recovery during reperfusion (Figure 3 ). These effects are likely due at least in part to titin degradation by MMP-2, given the colocalization of MMP-2 with titin near the Z disk of cardiac sarcomeres, the susceptibility of titin to degradation by MMP-2, and the reduction in I/R-induced titin degradation in hearts from MMP-2 knockout mice or in rat hearts in which MMP activity was selectively blocked with ONO-4817. A significant increase in MMP-2 activity was seen in the heart after experimental Trypanosoma cruzi infection (the parasite responsible for Chagas disease), and mortality was markedly reduced upon treatment with an MMP inhibitor, suggesting a role of MMP-2 in mediating acute Chagas cardiomyopathy. 40 Putative titin degradation products were detected in the plasma of patients with Chagas disease, 34 further supporting a role of MMP-2 in titin degradation. Moreover, myocardial infarction is associated with a significant right shift in the left ventricle pressure-volume relation (an observation consistent with titin degradation in the heart), and the broad-spectrum MMP inhibitor PD-166793 was shown to protect against this shift. 41 Although cardiac mechanical function at the end of perfusion is inversely related to ratios of T2 to MHC in hearts ( Figures 3B  and 4C ), caution is needed in relating this effect exclusively to titin degradation. As mentioned, other sarcomeric/cytoskeletal proteins, including troponin I, myosin light chain-1, and ␣-actinin, are also susceptible to degradation by MMP-2 under conditions of myocardial oxidative stress injury. However, our work clearly suggests that titin proteolysis is an important factor that negatively affects myocardial contractility on I/R injury.
Titin content in rat ventricles was investigated here by SDS-agarose gel electrophoresis or immunofluorescence staining against titin epitopes at the PEVK domain. Our electrophoresis results showed the Ϸ60% elevation in the ratio of T2 to MHC in the I/R group compared with aerobic control hearts. Immunofluorescence data also showed a reduction of titin immunostaining in the I/R group using the 9D10 antibody. In addition to degradation, posttranslational modifications of titin may have occurred upon I/R that led to diminished binding of titin antibodies to the specific epitopes. Posttranslational modifications of many cardiac myofilament/ cytoskeletal proteins during I/R, including actin 42 and myosin light chain-1, 43 have been reported in previous studies.
Our study does not rule out the possible action of other proteases in titin degradation. Calpains are most likely involved in sarcomeric protein degradation after ischemic episodes more severe than that observed in our model. 44 Indeed, calpain was shown to be able to cleave titin only after 24 hours of doxorubicin treatment of rat cardiomyocytes. 45 The ubiquitin-proteasome system is another proteolytic pathway that may be involved in titin degradation. Increased proteasome activities have been reported in various models of I/R injury. 46 -48 Moreover, the E3 ubiquitin-ligase MURF1 is known to be associated with the M-line region of titin 49 and ubiquitinates titin in yeast 2-hybrid screens. 50 In a rat heart failure model, both a loss of titin 51 and an increase in MMP-2 gene expression 52 were observed in diaphragm muscle. However, in our short-term experiments, we did not observe a significant loss of intact titin on I/R injury. We speculate that MMP-2 activation not only results in titin cleavage but also may trigger a cascade of proteolytic events leading to titin loss several hours after reperfusion.
Conclusions
The present results indicate that MMP-2 cleaves titin during either ex vivo or in vivo I/R injury. Furthermore, MMP-2 inactivation by pharmacological or genetic approaches protects against titin degradation. Our previous findings of troponin I, 14 myosin light chain-1, 15 and ␣-actinin 17 cleavage by MMP-2, in addition to our present results with titin, suggest that MMP-2 plays a crucial role in the pathogenesis of acute I/R injury at the level of the sarcomere and cytoskeleton. Whether MMP-2 causes contractile protein alterations in other cardiac pathologies needs further investigation. Pharmacological inhibition of MMP activity could represent a useful strategy for the prevention and/or treatment of myocardial I/R injury. 
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CLINICAL PERSPECTIVE
In addition to the well-known extracellular effects of matrix metalloproteinases (MMPs), we provide evidence that MMP-2 is localized inside the cardiac myocyte, near the Z-disk region of the sarcomere. We also show that upon acute ischemia/reperfusion injury, MMP-2 is activated and proteolyses titin, the largest known protein that plays a crucial role in both the diastolic and systolic function of the heart. Titin contains several cleavage motifs for MMP-2, and its proteolysis is reduced in hearts protected by pharmacological inhibition of MMP activity and in MMP-2-deficient hearts. This study provides new insights into the pathophysiological mechanism of ischemia/reperfusion injury and suggests that MMP inhibitors might be a useful strategy for reducing reperfusion injury. cm Sepharose CL2B column maintained at 1°C. On occasion the titin at this stage was also passed through a QSepharose column as described by Nave et al. 3 The purification was monitored by SDS-polyacrylamide electrophoresis in gradient slab gels (4% to 15%). Samples for these were dissociated at 56°C for 20 min in SDS/urea, as described by Fritz et al. 4 
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Skinned cardiomyocyte preparation
Skinned cardiomyocytes were isolated as described previously 5 . Briefly, mice were anesthesitized via isoflurane inhalation, sacrificed via cervical dislocation, and the heart was rapidly (< 90 seconds) cannulated via the aorta. The heart was then perfused for 4 min with perfusion buffer (113 NaCl, 4.7 KCl, 0.6 Na2HPO 4 , 1.2 MgSO 4 , 12 NaHCO 3 , 10 KHCO 3 , 10 HEPES, and 30 taurine, all in mmol/L) and then switched to digestion buffer (perfusion buffer plus 0.148 mg/ml Liberase blendzyme 2, 0.13 mg/ml of trypsin, 12.5 µmol/L CaCl 2 ) for 8-10 min. When the heart was flaccid, digestion was halted and the heart was placed in myocyte stopping buffer 1 (perfusion buffer plus 0.04 ml bovine calf serum (BCS)/ml buffer and 5 µmol/L CaCl 2 ). The left ventricle was cut into small pieces, triturated several times with a transfer pipet, filtered through a 300 µm nylon mesh filter and the filtered cells were gravity pelleted. We added 10 ml of myocyte stopping buffer 2 (perfusion buffer plus 0.05 ml BCS/ml buffer and 12. 
Analysis of titin by gel electrophoresis
Titin was analyzed in rat ventricular extracts at the end of the 110 min working heart perfusion protocol using 1%
vertical SDS-agarose gel electrophoresis as previously described 6 . Briefly, the frozen ventricles were pulverized under The immunolabeled cryosections were observed by confocal microscopy (LSM 510, Carl Zeiss Co., Jena, Germany). Cy3 (red) was scanned with a helium/neon green laser (543 nm) with a band pass 565 -615 nm filter (565 -615 nm excitation). Alexa488 (green) was captured using an argon laser (488 nm) with band pass 500 -530 filter (500 -530 nm excitation). DRAQ5 (blue) for nuclei was obtained with a helium/neon red laser (633 nm) with a long pass 650 nm filter. All confocal images were exported as TIFF files without any modifications by LSM 510 Image.
b-Titin 9D10 immunostaining
At the end of the 110 min working heart perfusion protocol some Control, I/R or I/R + ONO-4817 hearts were fixed and cryoprotected as described above. The cryoprotected hearts were cryosectioned and dried at room temperature. The dried cryosections were rinsed and titin immunolabeling was accomplished using 9D10 antibody (mouse anti-titin 9D10 
In silico analysis
According to Turk et al. 7 and Chen et al. 8 three MMP-2 cleavage motifs were chosen. These are PVS↓LRS, PVG↓LLA and L/ISR↓LTA with MMP-2 cleavage site indicated by the arrow. These consensus sequences were shown to be optimal MMP-2 cleavage motifs and, importantly, they showed high selectivity towards MMP-2 in comparison to other
MMPs including MMP-1, MMP-3, MMP-7, MMP-9 and MMP-14 7 . These consensus sequences were aligned vs. N2B mouse and human titin and the result was restricted to the top 20 with more than 60% homology using the SIM Alignment tool for protein sequence. The overlay assay was performed using the transferred membrane as described previously 9 followed by western blot. Briefly, membranes were blocked in blocking buffer (Odyssey, 927-40000) 1 Moreover, recent proteomic screens for MMP substrates have shown that MMPs regulate a host of signaling molecules, such as chemokines, both directly and indirectly. 2 The novel functions of MMPs are also crucial to the cardiovascular system. MMP enzymes can regulate, for instance, the bioavailability of vascular endothelial growth factor and the potent vasodilator adrenomedullin. 2 The diverse roles of MMPs are relevant not only for physiological processes such as heart development but also for pathological processes such as remodeling events resulting from myocardial infarction, hypertensive heart disease, or cardiomyopathy. 3 hand, titin is notorious for rapid degradation ex vivo: Protease inhibitors are required to keep titin intact. 12 A curious correlation has been found between the extent of titin-isoform transitions in chronic ischemic human heart disease and the degree of cardiac troponin-I degradation or complex formation. 12 A candidate enzyme potentially degrading titin is the ubiquitous Ca 2ϩ -dependent protease calpain-1, which has been implicated in the pathogenesis of myocardial dysfunction after I/R. Indeed, calpain-1 binds titin near the Z-disk 19 and in vitro degrades various cytoskeletal and myofibrillar proteins isolated from human cardiac tissue, including titin. 20 Titin is also proteolyzed in cultured rat cardiomyocytes after doxorubicin treatment to induce calpain-1. 21 Similar to calpain-1, MMP-2 targets a subset of structural and regulatory sarcomeric proteins, including titin (Figure) .
The important news is that MMP-2 is activated by oxidative stress after I/R and degrades titin both in an ex vivo working rat heart model of I/R and in an in vivo mouse model of I/R. 8 However, it remains to be answered unambiguously whether the degradation of titin and other intracellular target proteins under oxidative stress in vivo is due mainly to the activity of MMP-2 or calpain-1 or both. The authors address this issue by showing reduced titin degradation in hearts from MMP-2 knockout mice subjected to I/R in vivo, suggesting that MMP-2 really does the job, at least in part. 8 Along the same line, titin cleavage induced by I/R damage was diminished by an MMP inhibitor. In summary, in light of the importance of titin for diastolic and systolic function, titin degradation by MMP-2 (and perhaps calpain-1) likely contributes to the acute contractile depression developing in stunned myocardium. 
, which activates MMP-2. The MMP is found, among others, in the nucleus and mitochondria and at the cytoskeleton and caveolae. In the sarcomeres, activated MMP-2 degrades troponin-I (TnI) on the thin filaments, myosin light chain-1 (MLC-1) on the thick filaments, ␣-actinin in the Z-disk, and titin. MMP-2 binding to titin may preferentially occur near the Z-disk, whereas cleavage of titin could take place at multiple sites in the Z-disk, I-band, A-band, and M-band portions. Titin cleavage by MMP-2 might add to the acute myocardial contractile dysfunction in I/R. MMP-2 can also trigger signaling events leading to either necrosis or apoptosis. In the extracellular compartment, MMP-2 can be activated by proteolytic cleavage.
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Activation of MMP-2 During I/R Injury
The intracellular activation of MMP-2 as an effector of acute myocardial I/R injury in cardiomyocytes occurs via generation of peroxynitrite, a highly pro-oxidant species that increases to cardiotoxic levels within the first minutes of I/R. 4 Peroxynitrite activates cytosolic MMP-2 from an inactive precursor state, and MMP-2 now executes its actions on the sarcomeric proteins, troponin-I, myosin light chain-1, ␣-actinin, and titin ( Figure) . Ali et al 8 propose that MMP-2 binding to titin occurs preferentially near the Z-disk, as suggested by colocalization of immunofluorescence signals for MMP-2 and Z-disk-adjacent titin antibodies. However, the MMP-2 binding site(s) on titin still need to be mapped precisely. Whether the binding sites on titin are also the sites of titin cleavage is another open question. From sequence analysis, the authors predict potential cleavage sites in various regions along the titin filament, including the Z-disk-flanking, I-band, and A-band segments (Figure) . Providing experimental evidence in support of these predictions could be a challenging task, given the huge size (3000 to 4000 kDa) of the titin molecule.
Despite convincing evidence showing that MMP-2 degrades titin, it is not clear whether this cleavage, or even that of other sarcomeric proteins, is the principal cause of reduced cardiac work output during I/R injury. More likely, the contractile depression after oxidative stress has additional causes. MMP-2 by itself probably has biological actions in other subcellular compartments, such as caveolae, mitochondria, and the nucleus, as well as in the extracellular space (Figure) . The nature of these actions is still largely unknown, but both acute and long-term effects on contractile performance triggered by I/R damage could originate here. Finally, MMP-2 has links to signaling molecules associated with the development of apoptosis or necrosis, and it has been discussed that higher levels of oxidative stress could preferentially induce these pathways, causing irreversible cell injury. 4 
Conclusion
The article by Ali et al 8 is important because it demonstrates for the first time an acute effect of a protease, MMP-2, on the stability of the giant elastic protein titin as a consequence of oxidative stress during I/R. The finding provides another piece of evidence for an intracellular role of MMP-2. The study also uncovers a previously unrecognized link between the 2 components principally responsible for myocardial passive stiffness: extracellular matrix proteins ("classically" degraded by MMPs) and titin filaments. Both components are remodeled in heart disease, with detrimental effects on cardiac performance. Inhibiting MMP-2 activity by pharmacological intervention could be a desirable cardioprotective strategy in I/R injury and possibly also in chronic heart failure.
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